Comparative study of adjuvants for allergen-specific immunotherapy in a murine model

被引：12

作者：

Vazquez de la Torre, Maria ^{[1
]}

Luisa Baeza, Maria ^{[2
,3
,4
]}

Najera, Laura ^{[5
]}

Manuel Zubeldia, Jose ^{[2
,3
,4
]}

机构：

[1] Infanta Leonor Univ Hosp, Allergy Serv, Madrid, Spain

[2] Gregorio Maranon Univ Gen Hosp, Allergy Serv, Madrid, Spain

[3] Biomed Res Network Rare Dis CIBERER U761, Madrid, Spain

[4] Gregorio Maranon Hlth Res Inst, Madrid, Spain

[5] Puerta Hierro Majadahonda Univ Hosp, Patol Serv, Madrid, Spain

来源：

IMMUNOTHERAPY | 2018年 / 10卷 / 14期

关键词：

adjuvants; allergen-specific immunotherapy; allergic asthma; aluminum hydroxide; calcium phosphate; immunostimulatory sequences; monophosphoryl lipid A; murine model; INDUCED AIRWAY INFLAMMATION; IGE ANTIBODY-FORMATION; CPG OLIGODEOXYNUCLEOTIDES; IMMUNE-RESPONSE; IMMUNOSTIMULATORY DNA; EXPERIMENTAL ASTHMA; TH1; RESPONSES; MICE; HYPERRESPONSIVENESS; INDUCTION;

D O I：

10.2217/imt-2018-0072

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: To compare the immunological and clinical changes induced by allergen-specific immunotherapy (AIT) using different adjuvants. Materials & methods:Olea europaea pollen-sensitized mice were treated with olea plus aluminum hydroxide, calcium phosphate, monophosphoryl lipid A (MPL) or immunostimulatory sequences (ISS). Results: Aluminum hydroxide seems to drive initially to a Th2-type response. Bacteria-derived adjuvants (MPL and ISS) skew the immune response toward Th1 and Treg pathways. Specific-IgE production was lower after AIT with MPL and ISS. Moreover, IgG2a production significantly increased in ISS-treated mice. Bacteria-derived adjuvants also improved the Th1 cytokine response due to IFN- higher secretion. In addition, they improved bronchial hyper-reactivity and lung inflammation. Conclusion: Bacteria-derived adjuvants may enhance the efficacy of AIT.

引用

页码：1219 / 1228

页数：10

共 50 条

[1] Adjuvants in allergen-specific immunotherapy
Klimek, L.
Kramer, M.
Pfaar, O.
ALLERGOLOGIE, 2017, 40 (02) : 46 - 49
[2] Adjuvants in Allergen-Specific Immunotherapy
Gajdanowicz, P.
Pfaar, O.
Jutel, M.
ALLERGOLOGIE, 2018, 41 (09) : 427 - 434
[3] Perspectives in vaccine adjuvants for allergen-specific immunotherapy
Fili, Lucia
Cardilicchia, Elisa
Maggi, Enrico
Parronchi, Paola
IMMUNOLOGY LETTERS, 2014, 161 (02) : 207 - 210
[4] Adjuvants and formulations for allergen-specific sublingual immunotherapy
Van Overtvelt, L.
Lombardi, V.
Saint-Lu, N.
Mascarell, L.
Tourdot, S.
Moingeon, P.
REVUE FRANCAISE D ALLERGOLOGIE ET D IMMUNOLOGIE CLINIQUE, 2008, 48 (03): : 127 - 129
[5] Novel vaccines and adjuvants for allergen-specific immunotherapy
Crameri, Reto
Rhyner, Claudio
CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (06) : 761 - 768
[6] Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response
Zubeldia, J. M.
Ferrer, M.
Davila, I
Justicia, J. L.
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2019, 29 (02) : 103 - 111
[7] Allergen-specific immunotherapy: Power of adjuvants and novel predictive biomarkers
Sokolowska, Milena
Boonpiyathad, Tadech
Escribese, Maria M.
Barber, Domingo
ALLERGY, 2019, 74 (11) : 2061 - 2063
[8] New and old adjuvants in allergen-specific immunotherapy: With a focus on nanoparticles
Feng, Zhongtao
Yi, Xin
Hajavi, Jafar
JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (02) : 863 - 876
[9] Allergen-specific immunotherapy
Treudler, R.
Pfuetzner, W.
HAUTARZT, 2021, 72 (09): : 749 - 750
[10] Novel adjuvants in allergen-specific immunotherapy: where do we stand?
Lin, Yen-Ju
Zimmermann, Jennifer
Schuelke, Stefan
FRONTIERS IN IMMUNOLOGY, 2024, 15

← 1 2 3 4 5 →